Case number 1:23-cv-01372
Bayer Pharma AG et al v. Aurobindo Pharma Limited et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| May 10, 2024 | 22 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,828,310 B2. (Attachments: # 1 Order)(nms) (Entered: 05/10/2024) (0) |
| May 10, 2024 | N/A | CASE CLOSED per entry of D.I. 21 . (nms) (Entered: 05/10/2024) (0) |
| May 10, 2024 | 21 | SO ORDERED Granting (D.I. 20 in 23-cv-1372-RGA; D.I. 267 in 21-md-03017-RGA-LDH) Stipulation of Dismissal (*Party Aurobindo Pharma USA Inc. and Aurobindo Pharma Limited terminated). Signed by Judge Richard G. Andrews on 5/10/2024. Associated Cases: 1:21-md-03017-RGA-LDH, 1:23-cv-01372-RGA(nms) (Entered: 05/10/2024) (2) |
| May 10, 2024 | 20 | STIPULATION of Dismissal as to Defendants Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc. with prejudice, by Bayer AG, Bayer Pharma AG, Janssen Pharmaceuticals, Inc.. (Fahnestock, Derek) Modified on 5/10/2024 (nms). (Entered: 05/10/2024) (2) |
| Mar 4, 2024 | N/A | Pro Hac Vice Attorneys Timothy H. Kratz, Michael P. Hogan, and George J. Barry, III for Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 03/04/2024) (0) |
| Mar 1, 2024 | N/A | SO ORDERED, re (D.I. 18 in 23-cv-1372-RGA; D.I. 239 in 21-md-3017-RGA-LDH) MOTION for Pro Hac Vice Appearance of Attorney Timothy H. Kratz, George J. Barry, III, and Michael P. Hogan, filed by Aurobindo Pharma Limited, Aurobindo Pharma USA Inc.. Signed by Judge Richard G. Andrews on 3/1/2024. Associated Cases: 1:23-cv-01372-RGA, 1:21-md-03017-RGA-LDH(nms) (Entered: 03/01/2024) (0) |
| Mar 1, 2024 | 19 | Pro Hac Vice Fee - Credit Card Payment received for Timothy H. Kratz, George J. Barry, III, and Michael P. Hogan. ( re 18 MOTION for Pro Hac Vice Appearance of Attorney Timothy H. Kratz, George J. Barry, III, and Michael P. Hogan )( Payment of $ 150, receipt number ADEDC-4351337).(Myer, R.) (Entered: 03/01/2024) (0) |
| Feb 29, 2024 | 18 | MOTION for Pro Hac Vice Appearance of Attorney Timothy H. Kratz, George J. Barry, III, and Michael P. Hogan - filed by Aurobindo Pharma Limited, Aurobindo Pharma USA Inc.. (Myer, R.) (Entered: 02/29/2024) (4) |
| Feb 23, 2024 | 17 | NOTICE OF SERVICE of Production of Defendants' Core Technical Documents Pursuant to Paragraph 4(b) of the Delaware Default Standard for Discovery and Pursuant to the Standing Order Regarding Hatch-Waxman Cases in Which Infringement is Alleged filed by Aurobindo Pharma Limited, Aurobindo Pharma USA Inc..(Myer, R.) (Entered: 02/23/2024) (3) |
| Feb 23, 2024 | 16 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Aurobindo Pharma Limited for Aurobindo Pharma USA, Inc. filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc.. (Myer, R.) (Entered: 02/23/2024) (2) |
| Feb 23, 2024 | 15 | ANSWER to 1 Complaint, by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 02/23/2024) (16) |
| Feb 5, 2024 | N/A | SO ORDERED, re 14 STIPULATION TO EXTEND TIME to Answer, Move or Otherwise Respond to Complaint to February 23, 2024. Signed by Judge Richard G. Andrews on 2/5/2024. (nms) (Entered: 02/05/2024) (0) |
| Feb 5, 2024 | 14 | STIPULATION for Extension of Time to Answer, Move or Otherwise Respond to Complaint to February 23, 2024 - filed by Aurobindo Pharma Limited, Aurobindo Pharma USA Inc.. (Myer, R.) Modified on 2/5/2024 (nms). (Entered: 02/05/2024) (3) |
| Jan 26, 2024 | 13 | STIPULATION for Extension of Time to Answer, Move or Otherwise Respond to Complaint to February 9, 2024 - filed by Aurobindo Pharma Limited, Aurobindo Pharma USA Inc.. (Myer, R.) Modified on 1/26/2024 (nms). (Entered: 01/26/2024) (3) |
| Jan 26, 2024 | N/A | SO ORDERED, re (D.I. 212 in 21-md-3017-RGA-LDH; D.I. 13 in 23-cv-1372-RGA) STIPULATION for Extension of Time to Answer, Move or Otherwise Respond to Complaint to February 9, 2024. Signed by Judge Richard G. Andrews on 1/26/2024. Associated Cases: 1:21-md-03017-RGA-LDH, 1:23-cv-01372-RGA(nms) (Entered: 01/26/2024) (0) |
| Jan 26, 2024 | N/A | Reset Answer Deadlines: Aurobindo Pharma Limited answer due 2/9/2024; Aurobindo Pharma USA, Inc. answer due 2/9/2024. (nms) (Entered: 01/26/2024) (0) |
| Dec 29, 2023 | N/A | SO ORDERED, re 12 STIPULATION for Extension of Time (*Reset Answer Deadlines: Aurobindo Pharma Limited answer due 1/26/2024; Aurobindo Pharma USA, Inc. answer due 1/26/2024). Signed by Judge Richard G. Andrews on 12/29/2023. (nms) (Entered: 12/29/2023) (0) |
| Dec 28, 2023 | 12 | STIPULATION for Extension of Time to answer, move or otherwise respond to Complaint to January 26, 2024 - filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc.. (Myer, R.) Modified on 12/28/2023 (nms). (Entered: 12/28/2023) (3) |
| Dec 28, 2023 | 11 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Aurobindo Pharma Limited for Aurobindo Pharma USA, Inc. filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc.. (Myer, R.) (Entered: 12/28/2023) (2) |
| Dec 28, 2023 | 10 | NOTICE of Appearance by R. Touhey Myer on behalf of Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc. (Myer, R.) (Entered: 12/28/2023) (1) |
| Dec 11, 2023 | 9 | AFFIDAVIT of Service for Summons, Complaint and related papers served on Aurobindo Pharma Limited on December 8, 2023, filed by Bayer AG, Bayer Pharma AG, Janssen Pharmaceuticals, Inc.. (Fahnestock, Derek) (Entered: 12/11/2023) (8) |
| Dec 8, 2023 | 8 | SUMMONS Returned Executed by Bayer Pharma AG, Janssen Pharmaceuticals, Inc., Bayer AG.Aurobindo Pharma USA, Inc. served on 12/8/2023, answer due 12/29/2023. (Fahnestock, Derek) (Entered: 12/08/2023) (2) |
| Dec 6, 2023 | N/A | Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) (Entered: 12/06/2023) (0) |
| Dec 1, 2023 | N/A | Remark: MDL panel has been advised. (mkr) (Entered: 12/01/2023) (0) |
| Dec 1, 2023 | 7 | Summons Issued as to Aurobindo Pharma Limited on 12/1/2023; Aurobindo Pharma USA, Inc. on 12/1/2023. (Attachments: # 1 Summons Issued)(mkr) (Entered: 12/01/2023) (0) |
| Dec 1, 2023 | 6 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Johnson & Johnson for Janssen Pharmaceuticals, Inc. filed by Janssen Pharmaceuticals, Inc. (mkr) (Entered: 12/01/2023) (1) |
| Dec 1, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Bayer AG for Bayer Pharma AG filed by Bayer AG and Bayer Pharma AG. (mkr) (Entered: 12/01/2023) (1) |
| Dec 1, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,828,310 B2. (mkr) (Entered: 12/01/2023) (1) |
| Dec 1, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: No earlier than October 17, 2023. Date of Expiration of Patent: January 31, 2039.Thirty Month Stay Deadline: No earlier than April 17. 2026. (mkr) (Entered: 12/01/2023) (1) |
| Dec 1, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mkr) (Entered: 12/01/2023) (3) |
| Dec 1, 2023 | 1 | COMPLAINT filed against Aurobindo Pharma Limited, and Aurobindo Pharma USA, Inc. (Filing fee $ 405, receipt number ADEDC-4284983.) - filed by Bayer Pharma AG, Janssen Pharmaceuticals, Inc., and Bayer AG. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(mkr) (Entered: 12/01/2023) (0) |
